MedTrace Logo

Persistence of Immune Response After Vaccination With MCC

NCT00310687 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1244

Last updated 2014-09-19

No results posted yet for this study

Summary

Persistence of Immune response after vaccination with MCC

Conditions

  • Prevention of Meningococcal Infection

Interventions

PROCEDURE

BLOOD DRAW

Sponsors & Collaborators

  • Novartis Vaccines

    collaborator INDUSTRY

  • Novartis

    lead INDUSTRY

Principal Investigators

  • Vaccines - Information Services · Novartis Vaccines & Diagnostics

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
11 Years
Max Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2005-12-31
Completion
2005-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00310687 on ClinicalTrials.gov